QIMR Berghofer Medical Research Institute

Kazia Therapeutics Launches Phase 1b Trial of Paxalisib with Immunotherapy for Advanced Breast Cancer

4 months ago

• Kazia Therapeutics has initiated the ABC-Pax trial to evaluate paxalisib combined with immunotherapy in advanced breast cancer patients. • The Phase 1b study will assess the safety and efficacy of paxalisib with pembrolizumab or olaparib in triple-negative breast cancer. • The trial utilizes a novel liquid biopsy platform for real-time monitoring of cancer and immune cell behavior during treatment. • This combination aims to reprogram dormant cancer cells, making them susceptible to immune attack, potentially improving patient outcomes.

Artefenomel-Piperaquine Combination Shows Synergistic Effects Against Malaria in Human Study

6 months ago

• A randomized, open-label trial assessed the interaction of artefenomel and piperaquine against malaria using the induced blood-stage malaria (IBSM) model. • The study found that the combination of artefenomel and piperaquine exhibits synergistic effects in killing Plasmodium falciparum parasites. • Pharmacokinetic/pharmacodynamic modeling was used to predict the efficacy of the drug combination, showing consistency with phase 2b trial results. • The findings support the potential of artefenomel-piperaquine as an effective treatment for malaria, warranting further clinical development.

FDA Approves Axatilamab for Chronic Graft-versus-Host Disease

6 months ago

• The FDA has granted accelerated approval to Axatilamab for chronic graft-versus-host disease (GVHD) in patients who have failed first-line treatments. • Axatilamab, a drug based on the research of Dr. Kelli MacDonald, works by suppressing harmful immune cells that cause chronic GVHD. • Clinical trials demonstrated that Axatilamab significantly reduced symptoms in up to 75% of patients with chronic GVHD. • This approval marks a significant advancement, offering a new treatment option for patients with limited alternatives for this debilitating condition.

Aethlon Medical's Hemopurifier Receives Ethics Approval for Cancer Trial in India

8 months ago

• Aethlon Medical's Hemopurifier has received ethics approval in India for a clinical trial targeting solid tumors resistant to anti-PD-1 therapies. • The trial will assess the safety, feasibility, and optimal dosage of Hemopurifier in patients with stable or progressive disease. • Hemopurifier aims to improve therapeutic response by removing tumor-produced extracellular vesicles from the bloodstream. • Aethlon anticipates beginning patient recruitment in Q4 2024, with the trial informing future oncology efficacy studies.

Phase I/IIa Clinical Trial of RH5.1/AS01B Vaccine for Blood-Stage Malaria Shows Promising Safety and Immunogenicity

4 years ago

A first-in-human, open-label, non-randomized, multi-center, dose escalation Phase I/IIa clinical trial evaluated the safety, immunogenicity, and efficacy of the RH5.1/AS01B vaccine against blood-stage malaria. The study involved healthy, malaria-naive adults aged 18 to 45, demonstrating the vaccine's potential to reduce parasite multiplication rate and its safety profile across different doses.